bromodomain adjacent to zinc finger domain 2AGenealiases: TIP5 · WALp3
Q-omics provides the consensus-scored BAZ2A profile across patient tissues and cancer cell-line models. BAZ2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BAZ2A is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, BAZ2A protein abundance shows 26,640 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where BAZ2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BAZ2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BAZ2A survival associations across molecular data types. BAZ2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BAZ2A RNA expression–survival associations across cancer types. High BAZ2A expression shows unfavorable associations in LIHC, ACC, CESC and PAAD, but favorable associations in KIRC and SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BAZ2A RNA expression.
This table summarizes BAZ2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BAZ2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BAZ2A shows higher tumor expression in HNSC, LIHC, KIRC, STAD, KIRP and LUSC. The HNSC box plot shows higher BAZ2A RNA expression in tumor versus normal tissue (log2 FC = +0.843, t-test p < 0.001).
This table shows molecular features associated with BAZ2A in patient tissues and cancer cell lines. In patient samples, BAZ2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BAZ2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
